Metformin use and the Risk of Gastrointestinal Malignancies in Diabetic Populations: A Meta-Analysis
Open Access
- 26 December 2020
- journal article
- review article
- Published by Peertechz Publications Private Limited in International Journal of Clinical Endocrinology and Metabolism
- Vol. 6 (1), 035-041
- https://doi.org/10.17352/ijcem.000052
Abstract
Metformin use has been associated with a decreased risk of cancer and improvement in overall cancer survival rates. However, scant data available regarding metformin’s role in the risk of Gastrointestinal (GI) malignancies in patients with type II diabetes.Keywords
This publication has 28 references indexed in Scilit:
- Metformin for primary colorectal cancer prevention in patients with diabetes: A case‐control study in a US populationCancer, 2014
- Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2014
- Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cellsFrontiers in Physiology, 2014
- Long‐term use of metformin and colorectal cancer risk in type II diabetics: a population‐based case–control studyCancer Medicine, 2014
- Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic‐based case–control studyInternational Journal of Cancer, 2014
- Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic ReviewPLOS ONE, 2013
- Diabetes and pancreatic cancerMolecular Carcinogenesis, 2011
- Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 DiabetesDiabetes Care, 2011
- Diabetes and CancerDiabetes Care, 2010
- Antidiabetic Therapies Affect Risk of Pancreatic CancerGastroenterology, 2009